Business Description
ORIC Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US68622P1093
Description
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 75.65 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 1.1 | |||||
| 3-Year EPS without NRI Growth Rate | 4.2 | |||||
| 3-Year FCF Growth Rate | 7 | |||||
| 3-Year Book Growth Rate | -19.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 12.4 | |||||
| 9-Day RSI | 15.18 | |||||
| 14-Day RSI | 22.84 | |||||
| 6-1 Month Momentum % | 158.82 | |||||
| 12-1 Month Momentum % | 178.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.39 | |||||
| Quick Ratio | 10.39 | |||||
| Cash Ratio | 10.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.4 | |||||
| Shareholder Yield % | -0.04 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -43.2 | |||||
| ROA % | -38.97 | |||||
| ROIC % | -262.45 | |||||
| ROC (Joel Greenblatt) % | -3564.58 | |||||
| ROCE % | -45.86 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.15 | |||||
| Price-to-Tangible-Book | 2.07 | |||||
| EV-to-EBIT | -3.48 | |||||
| EV-to-EBITDA | -3.51 | |||||
| EV-to-FCF | -4.45 | |||||
| Price-to-Net-Current-Asset-Value | 2.51 | |||||
| Price-to-Net-Cash | 2.57 | |||||
| Earnings Yield (Greenblatt) % | -28.74 | |||||
| FCF Yield % | -14.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ORIC Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.827 | ||
| Beta | 0.54 | ||
| Volatility % | 74.51 | ||
| 14-Day RSI | 22.84 | ||
| 14-Day ATR (€) | 0.333466 | ||
| 20-Day SMA (€) | 10.0925 | ||
| 12-1 Month Momentum % | 178.48 | ||
| 52-Week Range (€) | 4.44 - 14.8 | ||
| Shares Outstanding (Mil) | 67.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ORIC Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ORIC Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
ORIC Pharmaceuticals Inc Frequently Asked Questions
What is ORIC Pharmaceuticals Inc(FRA:4TZ)'s stock price today?
The current price of FRA:4TZ is €7.95. The 52 week high of FRA:4TZ is €14.80 and 52 week low is €4.44.
When is next earnings date of ORIC Pharmaceuticals Inc(FRA:4TZ)?
The next earnings date of ORIC Pharmaceuticals Inc(FRA:4TZ) is 2024-05-08 Est..
Does ORIC Pharmaceuticals Inc(FRA:4TZ) pay dividends? If so, how much?
ORIC Pharmaceuticals Inc(FRA:4TZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers